Coherus BioSciences (CHRS) Misses Q4 EPS by 19c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. QGEN
7. CSX
8. LRCX
9. NDAQ
10. BFH

Go back to Coherus BioSciences (CHRS) Misses Q4 EPS by 19c

Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results

February 27, 2020 4:01 PM EST

Full Year UDENYCA® Sales of $356.1 Million

Full Year Cash Flow from Operating Activities of $28.4 million

REDWOOD CITY, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2019. 

Fourth Quarter 2019 and Recent Corporate Highlights

Coherus commercial capabilities advanced its core mission to expand choice, improve patient access and lower healthcare costs in the United States:

UDENYCA® (pegfilgrastim-cbqv) launch continues to deliver... More